USSTOCK.TODAY
Regular Market
Log in Sign up

FDA rejects Summit Therapeutics lung cancer drug and approves GSK new drug

MarketWatch +1 · ·by G4L

SMMT
SMMT Summit Therapeutics Inc
$10.67 -9.73%
View chart & analysis →
  1. 1The FDA released a response on Tuesday detailing the reasons for rejecting Summit Therapeutics and Akeso's ivonescimab as a lung cancer treatment.
  2. 2Summit Therapeutics stated that the FDA's decision was due to a lack of clear survival benefit.
  3. 3The FDA approved Nelcarmi on Tuesday, related to GSK's $10.6 billion acquisition of Nuvalent in June.

So what's the key point?

What is the main point? Summit Therapeutics' lung cancer treatment did not receive approval, while GSK's new drug was approved.

Source MarketWatch +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →